中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 10
Oct.  2014
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2014  >  30(10): 1071-1075

Anxiety in mice with acute hepatic encephalopathy induced by thioacetamide

DOI: 10.3969/j.issn.1001-5256.2014.10.024

  • The First Hospital of Lanzhou University

  • Received Date: 2014-02-15
  • Published Date: 2014-10-20
    Abstract

  • Objective To evaluate the mental disorders in mice with thioacetamide ( TAA) -induced acute hepatic encephalopathy ( AHE) .Methods Thirty male Kunming mice were equally and randomly divided into two groups ( treatment group and control group) . Mice in the treatment group received an intraperitoneal injection of TAA ( 200 mg·kg-1·d-1for 3 days, up to 600 mg·kg-1) , as compared with the same volume of physiological saline in the control group. Neurological function score, light /dark box, open field, and elevated plus-maze test were used to determine behavioral parameters at 24 h after the model was established. Serum ammonia, aspartate amino transferase ( AST) , alanine aminotransferase ( ALT) , and total bilirubin ( TBil) were measured at 24 h post determination of behavioral parameters. Comparison between two groups was made by independent-samples t test. Results In the light /dark box test, the treatment group had significantly reduced residence time in the light box and number of shuttles between two boxes ( t =-4. 006, P < 0. 01; t =-2. 656, P < 0. 05) ; in the open field test, the treatment group had significantly reduced central distance, central time, and number of vertical movements ( t =-3. 639, P < 0. 05;t =-2. 294, P < 0. 05; t =-2. 282, P < 0. 05) , as well as increased grooming time ( t = 5. 992, P < 0. 01) ; meanwhile, the number of open-arm entries and residence time in the open arm for the treatment group were also reduced in the elevated plus-maze test, as compared with the control group ( t =-3. 584, P < 0. 05; t =-3. 992, P < 0. 05) . However, the total distance in the open field test showed no significant difference between the two groups ( t =-0. 96, P > 0. 05) . Moreover, compared with the control group, the treatment group had significantly higher levels of serum ammonia ( t =-3. 168, P < 0. 05) , ALT ( t = 4. 316, P < 0. 05) , AST ( t =-2. 581, P < 0. 05) , and TBil ( t =-9. 127, P < 0. 01) . Conclusion Mice with AHE induced by an intraperitoneal injection of low-dose TAA have anxiety-related behaviors; the anxiety-related behaviors are not associated with reduced locomotor activities.

     

    • FullText(HTML)
    • References(22)
  • [1]LES I, DOVAL E, FLAVIM, et al.Quality of life in cirrhosis is related to potentially treatable factors[J].Eur J Gastroenterol Hepatol, 2010, 22 (2) :221-227.
    [2]NARDELLI S, PENTASSUGLIO I, PASQUALE C, et al.Depression, anxiety and alexithymia symptoms are major determinants of health related quality of life (HRQoL) in cirrhotic patients[J].Metab Brain Dis, 2013, 28 (2) :239-243.
    [3]ROEST AM, THOMBS BD, GRACE SL, et al.Somatic/affective symptoms, but not cognitive/affective symptoms, of depression after acute coronary syndrome are associated with 12-month all-cause mortality[J].J Affect Disord, 2011, 131 (1-3) :158-163.
    [4]KAUHANEN J, KAPLAN G, COHEN R, et al.Alexithymia and risk of death in middle-aged men[J].J Psychosom Res, 1996, 41 (6) :541-549.
    [5]JIANG H, XIE Q.Advances in the diagnosis and treatment of hepatic encephalopathy[J].J Clin Hepatol, 2011, 27 (10) :1027-1031. (in Chinese) 姜浩, 谢青.肝性脑病临床诊治的进展[J].临床肝胆病杂志, 2011, 27 (10) :1027-1031.
    [6]FERENCI P, LOCKWOOD A, MULLEN K, et al.Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification:final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998[J].Hepatology, 2002, 35 (3) :716-721.
    [7]BUTTERWORTH RF, NORENBERG MD, FELIPO V, et al.Experimental models of hepatic encephalopathy:ISHEN guidelines[J].Liver Int, 2009, 29 (6) :783-788.
    [8]MIRANDA AS, RODRIGUES DH, VIEIRA LB, et al.A thioacetamide-induced hepatic encephalopathy model in C57BL/6 mice:a behavioral and neurochemical study[J].Arq Neuropsiquiatr, 2010, 68 (4) :597-602.
    [9]AVRAHAM Y, GRIGORIADIS N, POUTAHIDIS T, et al.Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice[J].Br J Pharmacol, 2011, 162 (7) :1650-1658.
    [10]LI X, RISBROUGH VB, CATES-GATTO C, et al.Comparison of the effects of the GABAB receptor positive modulator BHF177 and the GABAB receptor agonist baclofen on anxiety-like behavior, learning, and memory in mice[J].Neuropharmacology, 2013, 70 (2) :156-167.
    [11]CAROLA V, D'OLIMPIO F, BRUNAMONTI E, et al.Evaluation of the elevated plus-maze and open-field tests for the assessment of anxiety-related behaviour in inbred mice[J].Behav Brain Res, 2002, 134 (1-2) :49-57.
    [12]LAU AA, CRAWLEY AC, HOPWOOD JJ, et al.Open field locomotor activity and anxiety-related behaviors in mucopolysaccharidosis type IIIA mice[J].Behav Brain Res, 2008, 191 (1) :130-136.
    [13]NEWMAN MG, LLERA SJ, ERICKSON TM, et al.Worry and generalized anxiety disorder:a review and theoretical synthesis of evidence on nature, etiology, mechanisms, and treatment[J].Annu Revi Clin Psychol, 2013, 9:275-297.
    [14]RUSCIO A, CHIU W, ROY-BYRNE P, et al.Broadening the definition of generalized anxiety disorder:effects on prevalence and associations with other disorders in the National Comorbidity Survey Replication[J].J Anxiety Disord, 2007, 21 (5) :662-676.
    [15]GRANT B, HASIN D, STINSON F, et al.Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA:results from the National Epidemiologic Survey on Alcohol and Related Conditions[J].Psychol Med, 2005, 35 (12) :1747-1759.
    [16]SCHIENLE A, HETTEMA JM, CCEDA R, et al.Neurobiology and genetics of generalized anxiety disorder[J].Psychiatr Ann, 2011, 41 (2) :113-123.
    [17]YASSA M, HAZLETT R, STARK C, et al.Functional MRI of the amygdala and bed nucleus of the stria terminalis during conditions of uncertainty in generalized anxiety disorder[J].J Psychiatr Res, 2012, 46 (8) :1045-1052.
    [18]HERDEN C, BEINEKE A, HETZEL U, et al.Unusual manifestation of hepatic encephalopathy in two Irish wolfhound siblings[J].Vet Rec, 2003, 153 (22) :682-686.
    [19]CAULI O, LLANSOLA M, ERCEG S, et al.Hypolocomotion in rats with chronic liver failure is due to increased glutamate and activation of metabotropic glutamate receptors in substantia nigra[J].J Hepatol, 2006, 45 (5) :654-661.
    [20]SERGEEVA OA, SCHULZ D, DOREULEE N, et al.Deficits in cortico-striatal synaptic plasticity and behavioral habituation in rats with portacaval anastomosis[J].Neuroscience, 2005, 134 (4) :1091-1098.
    [21]LEKE R, BAK L, IVERSEN P, et al.Synthesis of neurotransmitter GABA via the neuronal tricarboxylic acid cycle is elevated in rats with liver cirrhosis consistent with a high GABAergic tone in chronic hepatic encephalopathy[J].J Neurochem, 2011, 117 (5) :824-832.
    [22]WESIERSKA M, KLINOWSKA HD, ADAMSKA I, et al.Cognitive flexibility but not cognitive coordination is affected in rats with toxic liver failure[J].Behav Brain Res, 2006, 171 (1) :70-77.
    • Relative Articles

  • Relative Articles

    [1]Zihan LIANG, Jiahui LI, Shuang CHENG, Zhuoya YUAN, Wenya RONG, Yajie LIU, Yujie HAO, Ruilin WANG. Mechanism of action of Polygonum multiflorum in inducing liver injury： A study based on signaling pathways[J]. Journal of Clinical Hepatology, 2024, 40(3): 626-632. doi: 10.12449/JCH240332
    [2]Zhiguo LI, Xun MA, Yongan YE, Xianzhao YANG. Regulatory effect of Kangxian Yiai Prescription in a rat model of precancerous lesions of liver cancer： A study based on the mTOR/HIF-1α/VEGF signaling pathway[J]. Journal of Clinical Hepatology, 2024, 40(10): 2049-2054. doi: 10.12449/JCH241019
    [3]Xing YANG, Shudi LI, Jiangkai LIU, Zhen WANG, Suling LI. Current research status of traditional Chinese medicine in the prevention and treatment of hepatocellular carcinoma by regulating the JAK/STAT signaling pathway[J]. Journal of Clinical Hepatology, 2023, 39(11): 2718-2729. doi: 10.3969/j.issn.1001-5256.2023.11.030
    [4]Xin ZHOU, Zhi WANG, Xueru HE, Yuhao FU, Xuejiao XUN, Ying LI, Zhanjun DONG. Research advances in signaling pathways associated with potential anti-liver fibrosis drugs and targets[J]. Journal of Clinical Hepatology, 2023, 39(12): 2932-2941. doi: 10.3969/j.issn.1001-5256.2023.12.027
    [5]Suriguga LU, Ting LIU, Dandan ZHU, Sijia YU, Liqing LU, Junjie DING. Research advances in hepatic fibrosis related signal pathways and anti-hepatic fibrosis drugs[J]. Journal of Clinical Hepatology, 2022, 38(5): 1161-1164. doi: 10.3969/j.issn.1001-5256.2022.05.039
    [6]Rui SONG, Jing LI, Hongju YANG, Minyue LI, Jing YOU. Role of signal transducer and activator of transcription 1 in regulation of Treg/Th17 balance in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(11): 2627-2631. doi: 10.3969/j.issn.1001-5256.2022.11.038
    [7]Xiaolu ZHAO, Chunyan ZHANG, Xiaoyang GAO, Yuehong MA. Mechanism of action of the Hippo/YAP pathway in the development and progression of liver fibrosis[J]. Journal of Clinical Hepatology, 2022, 38(7): 1654-1657. doi: 10.3969/j.issn.1001-5256.2022.07.037
    [8]Yujuan PENG, Jing YOU, Jing LI, Guangjun TANG. Role of the JAK/STAT/SOCS signaling pathway in hepatitis B virus-related liver diseases[J]. Journal of Clinical Hepatology, 2021, 37(6): 1435-1439. doi: 10.3969/j.issn.1001-5256.2021.06.045
    [9]Yannan XU, Ping LIU, Yongping MU. Effects of different subtypes of Numb protein subtypes on liver fibrosis-related signaling pathways[J]. Journal of Clinical Hepatology, 2021, 37(1): 169-172. doi: 10.3969/j.issn.1001-5256.2021.01.036
    [10]Deng YangYang, Ge ShanFei, Yu YanQing, Xiong Ying. Cell signaling pathways associated with liver fibrosis and potential therapeutic strategies[J]. Journal of Clinical Hepatology, 2020, 36(5): 1141-1145. doi: 10.3969/j.issn.1001-5256.2020.05.043
    [11]HUANG Qing, LI JingTao, LIU YongGang, WEI HaiLiang, YAN ShuGuang, GUO YingJun, CHANG ZhanJie. Regulatory effect of mTOR pathway-mediated autophagy in liver injury[J]. Journal of Clinical Hepatology, 2020, 36(11): 2621-2625. doi: 10.3969/j.issn.1001-5256.2020.11.051
    [12]Li Yao, Wang ZhiXin, Wen Hao, Wang HaiJiu, Cai RangDongZhi, Yu WenHao, Zhang Li, Fan HaiNing. Endoplasmic reticulum stress signaling pathway and its association with liver diseases[J]. Journal of Clinical Hepatology, 2020, 36(2): 464-467. doi: 10.3969/j.issn.1001-5256.2020.02.051
    [13]Zhao DongKang, Luo WeiWei, Yu ShuiPing. Role of the Wnt signaling pathway in the development and progression of liver fibrosis[J]. Journal of Clinical Hepatology, 2018, 34(11): 2415-2419. doi: 10.3969/j.issn.1001-5256.2018.11.033
    [14]Zhang Xu, Liu Ping, Mu YongPing. Relationship between the Notch signaling pathway and the development and progression of liver fibrosis[J]. Journal of Clinical Hepatology, 2018, 34(1): 181-183. doi: 10.3969/j.issn.1001-5256.2018.01.039
    [15]Peng Qin, Zhao ShenJun, Li Wu. Research advances in signaling pathways involved in the development of hepatic fibrosis[J]. Journal of Clinical Hepatology, 2017, 33(5): 954-958. doi: 10.3969/j.issn.1001-5256.2017.05.035
    [16]Zhong XiaoMao, Han BaoSheng. Research advances in signaling pathways involved in liver regeneration mediated by oval cells[J]. Journal of Clinical Hepatology, 2016, 32(12): 2399-2402. doi: 10.3969/j.issn.1001-5256.2016.12.037
    [17]Zhang ChaoYa, Zhao XiangXuan, Lu ZaiMing, Guo QiYong. Research advances in sorafenib- induced apoptotic signaling pathways in liver cancer cells[J]. Journal of Clinical Hepatology, 2016, 32(4): 816-820. doi: 10.3969/j.issn.1001-5256.2016.04.048
    [18]Liu Jia, Zhu QinMei, Hu HongYi, Wang Su. Research advances in Hedgehog signaling pathway in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2015, 31(2): 300-304. doi: 10.3969/j.issn.1001-5256.2015.02.041
    [19]Zhou XueLing, Yu ShuiPing. Role of Wnt signaling pathway in progression of liver cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(9): 1540-1542. doi: 10.3969/j.issn.1001-5256.2015.09.045
    [20]Pan Jin, Ju Jian. Current perspectives on the JAK/STAT signaling pathway and its activating factors in liver fibrosis[J]. Journal of Clinical Hepatology, 2013, 29(5): 393-396.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(4)

    1. 严伟，丁苗苗，刘斐，缪黎玮. 维生素A 维生素D及维生素E水平与儿童血脂异常的相关性. 中国妇幼保健. 2024(20): 3918-3921 .
    2. 李莹，吴云凤. 维生素E临床应用研究进展. 江苏卫生保健. 2023(05): 306-309 .
    3. 张丹，李嘉宝，周楠，刘畅，杨蕾. 血清维生素水平与消化道恶性肿瘤相关性分析. 临床军医杂志. 2021(07): 727-730 .
    4. 段娟，张松波. 维生素E在慢性病治疗中的研究进展. 临床合理用药杂志. 2021(28): 178-181 .

    Other cited types(6)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 21.5 %FULLTEXT: 21.5 %META: 71.3 %META: 71.3 %PDF: 7.2 %PDF: 7.2 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 7.9 %其他: 7.9 %其他: 1.5 %其他: 1.5 %Bengaluru: 0.3 %Bengaluru: 0.3 %China: 0.9 %China: 0.9 %Hanoi: 0.1 %Hanoi: 0.1 %India: 0.2 %India: 0.2 %Russian Federation: 0.3 %Russian Federation: 0.3 %Seattle: 0.1 %Seattle: 0.1 %Szeged: 0.1 %Szeged: 0.1 %United States: 0.9 %United States: 0.9 %上海: 2.5 %上海: 2.5 %东莞: 0.1 %东莞: 0.1 %中卫: 0.1 %中卫: 0.1 %兰州: 0.5 %兰州: 0.5 %北京: 12.1 %北京: 12.1 %北海: 0.1 %北海: 0.1 %北阿坎德: 0.3 %北阿坎德: 0.3 %南京: 0.4 %南京: 0.4 %南充: 0.1 %南充: 0.1 %南宁: 0.3 %南宁: 0.3 %南阳: 0.1 %南阳: 0.1 %印度泰米尔纳德: 0.1 %印度泰米尔纳德: 0.1 %合肥: 0.1 %合肥: 0.1 %吉林: 2.1 %吉林: 2.1 %呼和浩特: 0.4 %呼和浩特: 0.4 %天津: 0.4 %天津: 0.4 %宁波市慈溪: 0.2 %宁波市慈溪: 0.2 %定西: 0.1 %定西: 0.1 %宿迁: 0.3 %宿迁: 0.3 %崇左: 0.2 %崇左: 0.2 %常德: 0.1 %常德: 0.1 %广州: 0.8 %广州: 0.8 %广西贵港: 0.1 %广西贵港: 0.1 %延安: 0.1 %延安: 0.1 %张家口: 3.6 %张家口: 3.6 %徐州: 0.1 %徐州: 0.1 %德黑兰: 0.1 %德黑兰: 0.1 %成都: 0.7 %成都: 0.7 %拉合尔: 0.1 %拉合尔: 0.1 %新乡: 1.1 %新乡: 1.1 %昆明: 0.3 %昆明: 0.3 %晋城: 0.2 %晋城: 0.2 %杭州: 0.8 %杭州: 0.8 %武汉: 0.7 %武汉: 0.7 %沈阳: 0.3 %沈阳: 0.3 %泉州: 0.1 %泉州: 0.1 %泰州: 0.2 %泰州: 0.2 %济南: 0.2 %济南: 0.2 %海得拉巴: 0.1 %海得拉巴: 0.1 %淮安: 0.2 %淮安: 0.2 %淮安市淮安区: 0.1 %淮安市淮安区: 0.1 %深圳: 0.1 %深圳: 0.1 %深圳市龙华区: 0.1 %深圳市龙华区: 0.1 %温州: 0.1 %温州: 0.1 %湖州: 0.1 %湖州: 0.1 %湘潭: 0.1 %湘潭: 0.1 %玉林: 0.4 %玉林: 0.4 %盐城: 0.1 %盐城: 0.1 %石家庄: 0.1 %石家庄: 0.1 %芒廷维尤: 26.6 %芒廷维尤: 26.6 %芝加哥: 0.2 %芝加哥: 0.2 %苏州: 0.2 %苏州: 0.2 %莫斯科: 2.3 %莫斯科: 2.3 %西宁: 11.3 %西宁: 11.3 %西安: 0.4 %西安: 0.4 %西安市新城区: 0.1 %西安市新城区: 0.1 %贵港: 0.5 %贵港: 0.5 %贵阳: 0.1 %贵阳: 0.1 %贺州: 0.1 %贺州: 0.1 %赤峰: 0.1 %赤峰: 0.1 %运城: 1.5 %运城: 1.5 %连云港: 0.1 %连云港: 0.1 %遵义: 0.1 %遵义: 0.1 %郑州: 3.5 %郑州: 3.5 %郑州市二七区: 0.1 %郑州市二七区: 0.1 %重庆: 0.3 %重庆: 0.3 %银川: 0.1 %银川: 0.1 %长春: 5.7 %长春: 5.7 %长沙: 1.2 %长沙: 1.2 %长治: 0.1 %长治: 0.1 %首尔: 0.3 %首尔: 0.3 %香港: 0.2 %香港: 0.2 %驻马店: 0.1 %驻马店: 0.1 %黄冈: 0.1 %黄冈: 0.1 %其他其他BengaluruChinaHanoiIndiaRussian FederationSeattleSzegedUnited States上海东莞中卫兰州北京北海北阿坎德南京南充南宁南阳印度泰米尔纳德合肥吉林呼和浩特天津宁波市慈溪定西宿迁崇左常德广州广西贵港延安张家口徐州德黑兰成都拉合尔新乡昆明晋城杭州武汉沈阳泉州泰州济南海得拉巴淮安淮安市淮安区深圳深圳市龙华区温州湖州湘潭玉林盐城石家庄芒廷维尤芝加哥苏州莫斯科西宁西安西安市新城区贵港贵阳贺州赤峰运城连云港遵义郑州郑州市二七区重庆银川长春长沙长治首尔香港驻马店黄冈

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (3040) PDF downloads(547) Cited by(10)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2183]YesterdayPV[4802]TodayIP[119]TodayPV[236]Online[12]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return